# Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma

> **NCT02611700** · PHASE3 · UNKNOWN · sponsor: **Biotech Pharmaceutical Co., Ltd.** · enrollment: 504 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinomas

## Interventions

- **DRUG:** Nimotuzumab
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02611700
- **Lead sponsor:** Biotech Pharmaceutical Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-11
- **Primary completion:** 2018-12
- **Final completion:** 2019-06
- **Target enrollment:** 504 (ESTIMATED)
- **Last updated:** 2016-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02611700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02611700, "Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02611700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*